Zhongke Borui, a Beijing brain-computer interface company spun out of the Chinese Academy of Sciences' Institute of Automation, has raised a round worth nearly RMB 100 million — roughly $14 million — led by Houji Capital and Muhua Kechuang, the company said. Kaisheng Capital served as exclusive long-term financial advisor on the deal, according to Vbdata. Domestically the round is labeled a B+ round; it is the company's second financing of 2026, following a tens-of-millions-of-yuan B round led by Sanze Ventures in March.
What Zhongke Borui builds
Zhongke Borui grew out of the Brain Network and Brain-Computer Interface Beijing Key Laboratory, under the leadership of chief scientist Jiang Tianzai, a researcher at the Institute of Automation. The company's products span three areas it calls brain function monitoring, brain function imaging and brain function evaluation, with its flagship devices being a noninvasive cerebral oximetry monitor and a wireless brain-oxygen headband that track blood oxygen levels in the brain in real time.
The company says its devices are already deployed in more than 600 hospitals in China and abroad, and have secured CE marking for sale in the European Union. That hospital footprint is unusually large for a brain-computer interface company at this funding stage, most of which are still in early clinical trials rather than commercial deployment.
How the money will be used
Zhongke Borui said the new capital will go toward expanding its senior technical team, accelerating development of its brain-computer interface product line, scaling manufacturing capacity, and pushing further into international markets beyond its current EU certification. The emphasis on manufacturing scale-up, rather than core research, reflects a company trying to convert hospital pilot deployments into recurring equipment sales.
Investors and competitors
Houji Capital and Muhua Kechuang lead this round; Sanze Ventures led the prior B round eight months earlier, making 2026 a two-financing year for the company. China's brain-computer interface sector has drawn a wave of capital in 2026, with rivals including Beijing-based BrainCo and NeuraMatrix also raising this year, while Boruikang — a separate company pursuing an IPO as China's prospective "first brain-computer interface stock" — has set a higher public-market bar for the sector. Zhongke Borui's pitch is narrower than most: rather than chase invasive neural implants, it has built a commercial business around noninvasive oxygen monitoring, a lower-regulatory-hurdle category that let it reach hundreds of hospitals faster than implant-focused peers.
What to watch next
With CE marking already in hand, the next test is whether Zhongke Borui can convert its 600-hospital footprint into recurring revenue and expand beyond Europe into other regulated markets such as the US. Investors will also be watching whether the company's noninvasive approach can keep pace commercially as rivals pursuing invasive brain-computer interfaces push toward clinical trials and public listings in 2027.